Axogen shares preliminary 2025 results update
Axogen, Inc. reported that it has released preliminary, unaudited financial results for its fourth quarter and full year 2025.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Axogen, Inc. reported that it has released preliminary, unaudited financial results for its fourth quarter and full year 2025. The company furnished these results through a press release dated January 12, 2026, attached as Exhibit 99.1 to this report. Axogen also posted an updated corporate presentation on its investor relations website and furnished it as Exhibit 99.2. Both the press release and the presentation are provided as “furnished,” not “filed,” meaning they are not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced.
8-K Event Classification
3 items: 2.02, 7.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Axogen (AXGN) disclose in this 8-K filing?
Axogen, Inc. furnished a press release with its preliminary, unaudited fourth quarter and full year 2025 financial performance and an updated corporate presentation as exhibits to this report.
Which financial period is covered by Axogen’s preliminary results in this filing?
The preliminary, unaudited results furnished by Axogen cover its fourth quarter and full year 2025 financial performance.
Where can investors find Axogen’s updated corporate presentation mentioned in the 8-K?
Axogen stated that the updated corporate presentation is posted on its website at https://ir.axogeninc.com/news-events and is also included as Exhibit 99.2 to this report.
Are Axogen’s preliminary 2025 results in this 8-K considered “filed” with the SEC?
No. Axogen specified that the information provided under Item 2.02 and Item 7.01, including Exhibits 99.1 and 99.2, is being furnished, not filed, and is not subject to Section 18 liability or automatically incorporated into other filings.
What exhibits are attached to Axogen’s January 12, 2026 8-K?
The exhibits are: 99.1, a press release dated January 12, 2026 regarding preliminary 2025 financial results; 99.2, a corporate presentation dated January 2026; and 104, the cover page interactive data file.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2026
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
(Address of principal executive offices)
(Zip Code)
(386 ) 462-6800
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On January 12, 2026, Axogen, Inc. (the “Company”) issued a press release announcing its preliminary, unaudited fourth quarter and full year 2025 financial performance. A copy of the press release is furnished as Exhibit 99.1.
The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 7.01 Regulation FD Disclosure.
On January 12, 2026, the Company also posted an updated corporate presentation to its website at https://ir.axogeninc.com/news-events. The Company may use the corporate presentation from time to time in conversation with analysts, investors, and others. A copy of the investor update is furnished as Exhibit 99.2.
The information in this Item 7.01, including Exhibit 99.2, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits
| (d) Exhibits | See the Exhibit index below, which is incorporated herein by reference. | ||||
Exhibit No. | Description | ||||
| 99.1 | Axogen Inc. Press Release dated January 12, 2026, regarding Preliminary 2025 Financial Results | ||||
| 99.2 | Axogen, Inc. Corporate Presentation, dated January 2026 | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AXOGEN, INC. | ||||||||
| Dated: January 12, 2026 | By: | /s/ Marc Began | ||||||
| Marc Began | ||||||||
| Executive Vice President, General Counsel and Chief Compliance Officer | ||||||||